ロード中...
Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
BACKGROUND: Rivaroxaban is an oral anticoagulant approved in the US for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). We determined the effectiveness and associated risks of rivaroxaban versus other oral anticoagulants in a large real-world popu...
保存先:
| 出版年: | BMC Cardiovasc Disord |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5585896/ https://ncbi.nlm.nih.gov/pubmed/28874129 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12872-017-0672-5 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|